Close Menu


AXA Diagnostics will market the miRview cancer tests in Italy.

A team of researchers from MD Anderson Cancer Center has published a proof-of-principle study demonstrating the usefulness of miRNA biomarkers in the blood for detecting pancreatic cancer.

Of that total, more than $2 million has been handed out to finance therapeutic RNAi research, including the development of new delivery approaches and treatments for HIV-1 and amyotrophic lateral sclerosis.

Papers of Note: Sep 3, 2009


RNAi-Related Papers Published August 2009

A Santaris official also said that while the company remains committed to microRNAs as drug targets, the company isn’t likely to advance additional miRNA drugs into the clinic in the near term as it takes a measured approach to selecting future clinical candidates.

The company also reported its financial results for the first half of 2009, posting a roughly 32 percent rise in revenues and a 28 percent jump in net losses.

IP Update: Aug 27, 2009


USPTO Publishes Three Patents, Ten Patent Applications Related to RNAi

American and Serbian researchers have identified telltale miRNA changes in the saliva of individuals with oral cancer — a finding that they say may eventually yield saliva-based oral cancer diagnostic tests.

The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.

SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.


The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.